Inner Quaternary Ammonium Salt (e.g., Betaine, Etc.) Patents (Class 514/556)
-
Patent number: 8067468Abstract: Salts of L-carnitine and alkanoyl L-carnitines with phytic acid of general formula (I), and the process of preparing the same, wherein the mole ratio between the L-carnitine or its alkanoyl derivatives cation and phytic acid anion be within the range of 1:1 to 6:1, wherein: n=1-6; R1 is the phytate anion; R is either hydrogen, a straight alkanoyl group having 2-12 carbon atoms or a branched-chain alkanoyl group having 2-12 carbon atoms.Type: GrantFiled: September 12, 2009Date of Patent: November 29, 2011Inventor: Jian Chen
-
Patent number: 8053472Abstract: The invention relates to the use of the acetyl L-carnitine in association with the biotin for the treatment of patients with Type 2 insulin-resistant diabetes mellitus.Type: GrantFiled: July 2, 2008Date of Patent: November 8, 2011Assignee: Sigma-Tau Industrie Farmaceutiche Riunite S.p.A.Inventor: Menotti Calvani
-
Publication number: 20110268817Abstract: It is described the use of L-carnitine, in combination with antioxidants such as vitamin E and inorganic elements such as manganese, zinc, sodium and potassium, for the preparation of a physiological supplement or medicament for opthalmic use, for the prevention or treatment of accomodative asthenopia.Type: ApplicationFiled: June 25, 2009Publication date: November 3, 2011Applicant: SIGMA-TAU INDUSTRIE FARMACEUTICHE RIUNITE S.P.A.Inventors: Nicola Pescosolido, Aleardo Koverech
-
Publication number: 20110268719Abstract: Annatto extract composition (AEC), including cis and trans geranyl geraniols (GG) and tocopherol-free C-5 unsubstituted tocotrienols (T3), increases the de novo synthesis of intermediate isoprenoid and distal protein products, including endogenous coenzyme Q10 (CoQ10), dolichols (DL) and all subsequent GG-prenylated and DL-glycosylated proteins, including GG-porphyrinated hemes. This intermediate and distal product replenishment by AEC reverses maladies of myotoxicity (of both drug and non-drug origins), including maladies that affect the muscle, kidney, eye, GI tract and skin, nerve, blood, and CoQ10-related syndromes of energetics and LDL protection. AEC anabolically increases the endogenous de novo CoQ10 synthesis via GG elongation/prenylation of side-chain and conversely CoQ10 catabolically increases the endogenous de novo GG synthesis via beta-oxidation of CoQ10. Also, such AEC decreases de novo synthesis and increases disposal of triglycerides (TG) in humans via PPAR activation and SREBP deactivation.Type: ApplicationFiled: July 13, 2011Publication date: November 3, 2011Applicant: AMERICAN RIVER NUTRITION, INC.Inventor: Barrie TAN
-
Patent number: 8048921Abstract: Carnitine and Taurine Compounds are described. The Carnitine Compound comprises Carnitine and one of a Nitrate and a Nitrite. The Taurine Compound comprises Taurine and one of a Nitrate and a Nitrite.Type: GrantFiled: December 17, 2008Date of Patent: November 1, 2011Inventors: Ronald Kramer, Alexander Nikolaidis
-
Publication number: 20110217252Abstract: It is described the use of propionyl L-carnitine for treating disturbances of the skin such as cellulite.Type: ApplicationFiled: November 5, 2009Publication date: September 8, 2011Applicant: SIGMA-TAU INDUSTRIE FARMACEUTICHE RIUNITE S.P.A.Inventor: Aleardo Koverech
-
Publication number: 20110206623Abstract: A subject-matter of the invention is formulations comprising novel zwitterionic compounds and the use of these formulations as cosmetics.Type: ApplicationFiled: June 24, 2008Publication date: August 25, 2011Applicant: EVONIK GOLDSCHMIDT GMBHInventors: Hans Henning Wenk, Holger Leidreiter, Mike Farwick, Petra Allef, Ursula Maczkiewitz, Sascha Herrwerth
-
Publication number: 20110200693Abstract: The present invention generally relates to increasing the efficiency of usage of an ingested exogenous biologically active substance by a body. In particular, the present invention relates to ways to improve the efficiency of utilization of ingested creatine in a body, in particular to increase the storage of creatine in the body. One embodiment of the present invention is the use of a combination comprising creatine and a soluble fiber for the preparation of a composition to increase the storage of creatine in the body.Type: ApplicationFiled: July 22, 2008Publication date: August 18, 2011Applicant: NESTEC S.A.Inventors: John Bruce German, Jacques Edouard Decombaz, Pierre Wuersch
-
Publication number: 20110196036Abstract: The present invention relates to use of betaine for protecting skin from biological irritation. The invention also relates to the use of betaine as a protecting agent in a cosmetic and/or toiletry preparation. The invention further relates to a method of protecting skin from biological irritation.Type: ApplicationFiled: October 15, 2009Publication date: August 11, 2011Applicant: DANISCO A/SInventor: Kirsti Jutila
-
Publication number: 20110190394Abstract: Subject of the invention is a method for the production of a carnitine granulate, which includes the steps of (a) providing an aqueous solution comprising at least 65% (w/w) carnitine, (b) providing a particulate carrier comprising silica, the carrier having an average particle size of more than 150 ?m, and (c) mixing the aqueous solution and the carrier. Another subject of the invention is a carnitine granulate.Type: ApplicationFiled: December 9, 2010Publication date: August 4, 2011Inventor: Thomas Büchner
-
Patent number: 7951842Abstract: This invention relates to the use of compounds of the general formula (I): R?—CONH—X—NR2R3—R4—Y in which R1 represents an alkyl moiety containing 11 to 21 carbon atoms, X stands for a (CH2)n- group and n is an integer from 1 to 6, R2 and R3 independently represent an alkyl moiety with 1 to 4 carbon atoms or an hydrogen atom, Y stands for a COO— group, in cosmetic compositions, characterized in that the compound of formula (I): is prepared by reacting the oil from Theo-broma grandiflorum with an amine of the formula (II): H2N—X—NR2R3 and subsequently reaction with sodium monochloroacetic acid.Type: GrantFiled: September 9, 2005Date of Patent: May 31, 2011Assignees: Cognis Brasil Ltda., Natura Cosmeticos S.A.Inventors: Rosa Maria Teixeira Tagé Biaggio, Setsuo Sato, Juliana Bucchi Alencastre, Carlos Alberto Moura, Henrique Sales, Tiago Costa Beber, Rosa Maria da Cunha Canto Friedlander, Tereza Maria de Senne Peranovich Victorio, Edjane dos Santos Lima
-
Publication number: 20110123654Abstract: A product comprising a) Russian Tarragon (Artemisia dracunculus), an extract of Russian Tarragon or a derivative thereof b) a creatine and/or carnitine compound or derivative or precursor thereof.Type: ApplicationFiled: June 5, 2009Publication date: May 26, 2011Inventors: Ralf Jaeger, Martin Purpura, Ivo Pischel
-
Publication number: 20110111066Abstract: Nutritional compositions are provided containing at least one PPAR agonist, at least one PGC-1alpha agonist, and at least one creatine derivative. Methods of promoting anabolism and improving or enhancing physical performance using the compositions are provided. The compositions and methods can be combined with physical training or exercise.Type: ApplicationFiled: November 9, 2010Publication date: May 12, 2011Applicant: BIO-ENGINEERED SUPPLEMENTS AND NUTRITION, INC.Inventors: Chris Ferguson, Sal Abraham
-
Publication number: 20110111040Abstract: A gold-creatine nanoparticle is described, preferably covered with albumin, together with a process for its preparation and its use as medicament, in particular for the treatment of stroke. Said gold nanoparticle is capable of crossing the blood-brain barrier.Type: ApplicationFiled: May 19, 2009Publication date: May 12, 2011Inventors: Silke Krol, Julian Lopez-Viota Gallardo
-
Publication number: 20110104137Abstract: Dosage forms and methods of use are disclosed for a) adjuncts administered individually or simultaneously with HMg-CoA reductase inhibitors (statins) and/or selective phosphodiesterase 5 inhibitors or, b) the administration of a conjugate consisting of the adjuncts and an HMG-CoA reductase inhibitor and/or a selective phosphodiesterase 5 inhibitor. The invention is useful in the amelioration of side effects associated with HMG-CoA reductase inhibitors and will improve their effectiveness in diseases for which these are useful. The invention will also improve the effectiveness in the of selective phosphodiesterase 5 inhibitors in patients using these medications alone or in conjunction with statins, for the treatment of erectile dysfunction.Type: ApplicationFiled: April 19, 2010Publication date: May 5, 2011Applicant: ChronoRX LLC, an Alaska Limited Liability CompanyInventors: Kenneth T. Richardson, Don C. Pearson
-
Patent number: 7928142Abstract: The present invention relates to a composition including at least one retinoid and at least one beta-aminoisobutyric acid derivative and the use thereof for the preparation of an article to be used for the topical application to skin, hair or nails.Type: GrantFiled: March 4, 2008Date of Patent: April 19, 2011Assignee: Johnson & Johnson Consumer France SASInventors: Thierry Oddos, Otto Von Stetten
-
Publication number: 20110086917Abstract: The use of L-carnitine, or one of its pharmaceutically acceptable salts, is described in combination with glucose for the preparation of a medicament useful for diminishing the number of deaths caused by acute myocardial infarction, for reducing the number of days infarction patients spend in intensive care in hospital, and for reducing the number of episodes of post-infarction heart failure, in which the L-carnitine is administered intravenously within only a few hours of the onset of symptoms of acute myocardial infarction at an initial dose of 9 grams a day in combination with 1000-1500 mL of a 5% glucose solution for 5 days, after which the L-carnitine treatment is continued at a dose of 4 grams a day administered orally.Type: ApplicationFiled: December 20, 2010Publication date: April 14, 2011Applicant: SIGMA-TAU INDUSTRIE FARMACEUTICHE RIUNITE S.P.A.Inventor: Aleardo Koverech
-
Publication number: 20110076321Abstract: A self-adhesive polymer matrix which comprises a polymer that forms a gel in water, water, a sea algae extract, and a monohydric or polyhydric alcohol.Type: ApplicationFiled: September 22, 2010Publication date: March 31, 2011Applicant: BEIERSDORF AGInventors: Karl-Heinz WOELLER, Thorsten BERG, Inge KRUSE, Rainer WOLBER
-
Patent number: 7915312Abstract: The present invention is directed to a physiological method for improving vision in a human patient. This method involves topical application to the eye, an amount of acetylcholine esterase inhibitor containing composition so that it is sufficient to provide a therapeutic benefit to improve the visual acuity in the human patient. The composition is administered topically and at bedtime after an eye straining work for about 20 minutes. The method disclosed herein is used for treatment and prevention of congenital and acquired color vision blindness, treatment of ocular hypertension and glaucoma, prevention of the progression of myopia, treatment of strabismus or squint, potentiation of best visual acuity, neuro-protection, treatment of aberrations secondary to pupil dilation.Type: GrantFiled: March 17, 2003Date of Patent: March 29, 2011Inventor: Gerard M. Nolan
-
Patent number: 7897641Abstract: A composition is disclosed which is suitable for the prevention and/or treatment of cell and tissue abnormalities of exogenous, toxic or metabolic origin and suitable for reducing the toxic effects of cyclosporin-A and other immunosuppressive agents, which may take the form of a food supplement or of an actual medicine, containing as its active ingredients in combination or separately packaged: (a) propionyl L-carnitine or one of its pharmacologically acceptable salts, and (b) an amino acid selected from the group consisting of glycine, serine, alanine and arginine, or mixtures thereof.Type: GrantFiled: February 20, 2001Date of Patent: March 1, 2011Assignee: Sigma-Tau Industrie Farmaceutiche Riunite S.p.A.Inventor: Claudio Cavazza
-
Patent number: 7884089Abstract: An antimicrobial coating composition consisting essentially of 70 to 80 wt. percent water; 5 to 10 wt. percent methyl alcohol; 3 to 8 wt. percent octadecyl dimethyl trimethoxy silylpropyl-ammonium chloride; 1 to 5 wt. percent chloropropyl trimethoxysilane; 0.5 to 1.5 wt. percent aminopropyltrialkoxysilane; 0.5 to 1.5 wt. percent of a surfactant; 1 to 1.5 wt. percent of an anti-microbial agent; and 0.5 to 2.5 wt. percent sulfuric acid.Type: GrantFiled: February 6, 2009Date of Patent: February 8, 2011Assignee: Xurex, Inc.Inventor: Bo H. Gimvang
-
Publication number: 20110027192Abstract: A fat-burning, energy-producing water composition. The water composition contains spring water and a premeasured, effective amount of L-carnitine dissolved in the spring water at a concentration of no less than 100 mg and no more than 2000 mg per 16 oz of spring water. The water composition may further include at least one nutritious component selected from the group consisting of vitamin B-6, L-Lysine. vitamin B-3, vitamin B-12 and any combination thereof. The water composition may be carbonated or uncarbonated, flavored or flavorless. The water composition in bottled water is administered to a mammal for quenching thirst and increasing fat-burning, improving energy, and keeping body slim and fit.Type: ApplicationFiled: March 9, 2009Publication date: February 3, 2011Inventor: Fabio Lanzoni
-
Patent number: 7879908Abstract: The use of L-carnitine, or one of its pharmaceutically acceptable salts, is described in combination with glucose for the preparation of a medicament useful for diminishing the number of deaths caused by acute myocardial infarction, for reducing the number of days infarction patients spend in intensive care in hospital, and for reducing the number of episodes of post-infarction heart failure, in which the L-carnitine is administered intravenously within only a few hours of the onset of symptoms of acute myocardial infarction at an initial dose of 9 grams a day in combination with 1000-1500 mL of a 5% glucose solution for 5 days, after which the L-carnitine treatment is continued at a dose of 4 grams a day administered orally.Type: GrantFiled: June 21, 2005Date of Patent: February 1, 2011Assignee: Sigma-Tau Industrie Farmaceutiche Riunite S.p.A.Inventor: Aleardo Koverech
-
Publication number: 20110021632Abstract: The present invention relates to the use of creatine compounds such as, for example, creatine, creatine phosphate or analogs of creatine, such as creatine-pyruvate, creatine-ascorbate, cyclocreatine, 3 guanidinopropionic acid, guanidinoacetate, homocyclocreatine, guanidino benzoates as energy generating systems and antioxidants for preservation of skin against adverse aging effects and damage secondary to insults such as harmful sun radiations, stress and fatigue. The creatine compounds which can be used in the present method include (1) creatine, creatine phosphate and analogs of these compounds which can act as substrates or substrate analogs for creatine kinase; (2) molecules that mimic the biological activity of creatine (3) molecules that modulate the creatine kinase system.Type: ApplicationFiled: February 24, 2010Publication date: January 27, 2011Applicant: AVICENA GROUP, INC.Inventor: Rima KADDURAH-DAOUK
-
Publication number: 20110020270Abstract: This invention discloses the use of an E-selectin antagonist and a mobilizer of hematopoietic stem cells or progenitor cells in methods and compositions for treating or preventing immunocompromised conditions resulting from medical treatment. The present invention is particular relevant for prophylaxis and/or treatment of hematopoeitic disorders including neutropenia, agranulocytosis, anemia and thrombocytopenia in individuals receiving or proposed to receive treatments that target rapidly dividing cells or that disrupt the cell cycle or cell division.Type: ApplicationFiled: December 9, 2008Publication date: January 27, 2011Inventors: Jean-Pierre Levesque, Ingrid Winkler
-
Publication number: 20110008461Abstract: A PEPCK inhibitor can include identifying a molecule that has a size capable of fitting into and interacting with the PEPCK binding site and at least one of the following: (a) a first terminal substituent having co-planar atoms acting as metal ligands to the active site metal ion PEPCK; (b) at least one of an atom or substituent at positions 2 or 3 from the first terminal substituent includes a neutral carbon center or include an oxygen, sulfur, selenium, or other atom with similar physiochemical properties; (c) at least one of an atom or substituent at positions 2 or 3 from the first terminal substituent is devoid of an electropositive atom or substituents; or (d) a second terminal substituent opposite of the first terminal substituent, said second terminal substituent having an atom that is a hydrogen boding acceptor and/or is negatively charged.Type: ApplicationFiled: July 12, 2010Publication date: January 13, 2011Inventors: Gerald Carlson, Todd Holyoak, Sarah Sullivan, Rose Mary Stiffin
-
Publication number: 20100303840Abstract: The present invention relates to the use of creatine compounds including creatine, creatine phosphate or analogs of creatine, such as cyclocreatine, for treating diseases of the nervous system. Creatine compounds can be used as therapeutically effective agents against a variety of diseases of the nervous system such as diabetic and toxic neuropathies, peripheral nervous system diseases, Alzheimer's disease, Parkinson's disease, stroke, Huntington's disease, amyotropic lateral sclerosis, motor neuron disease, traumatic nerve injury, multiple sclerosis, dysmyelination and demyelination disorders, and mitochondrial diseases.Type: ApplicationFiled: December 18, 2009Publication date: December 2, 2010Applicants: AVICENA GROUP, INC., THE GENERAL HOSPITAL CORPORATIONInventors: Rima KADDURAH-DAOUK, M. Flint BEAL
-
Publication number: 20100297040Abstract: In recent years the demand for cosmetic compositions and cosmetic methods for improving the appearance and condition of skin has grown enormously; consumers are seeking topical skin care products that help treat or delay the signs of natural (chronoaging) and environmental aging. The present invention relates to topical compositions for application to human skin and to their use in improving the condition and appearance of skin. It is based on the premise that effective treatment of normal skin conditions due to natural or environmental aging, such as wrinkles, lines, sagging, hyperpigmentation and age spots, and/or of sensitive, dry, rough, flaky, red, itchy, irritated skin may be obtained through the application of cosmetic compositions to the skin which comprise a combination of collagen stimulators, phytoestrogens, plant derived anti-inflammatory agents, fatty acid, antioxidants.Type: ApplicationFiled: April 2, 2010Publication date: November 25, 2010Inventor: Candace Rose Keefe
-
Patent number: 7834056Abstract: A composition for hyperuricemia disease or a related disorder, use thereof and method of using thereof are provided.Type: GrantFiled: July 18, 2007Date of Patent: November 16, 2010Inventor: Shuhua Gu
-
Publication number: 20100273880Abstract: The present invention relates to a storage-stable aqueous or gel-like composition or solution comprising a magnesium compound selected from a magnesium salt or a magnesium complex compound, and L-carnitine, and the use thereof for the preparation of a medicament for supporting metabolism, in particular in muscle tissue, and for supporting muscle structure, and its use as food supplement or in the veterinary sector as animal feed additive, in particular for horses, poultry, pigeons, pigs, cattle, sheep and camels.Type: ApplicationFiled: July 2, 2010Publication date: October 28, 2010Inventor: Günter Hopf
-
Publication number: 20100234459Abstract: Novel medical use of 3-(2,2,2-trimethylhydrazinium) propionate salts for the manufacture of a medicament for prevention and therapy of atherosclerosis.Type: ApplicationFiled: December 3, 2008Publication date: September 16, 2010Applicant: JSC GRINDEKSInventors: Ilmars Stonans, Eduard Tararak, Elena Andreyeva
-
Patent number: 7795204Abstract: Food supplement compositions and their methods of use in increasing lean mass and/or muscle size and/or strength in individuals, particularly, athletes is described. The food supplements described comprise a substance which increases nitric oxide production in the body, and, a source of amino acids. Other food supplements described comprise a substance which can enhance and/or mimic insulin activity, and a source of amino acids. The food supplement compositions described are suitable for supplementing the diet of an athlete and particularly for enhancing an athlete's muscle size or strength.Type: GrantFiled: March 11, 2004Date of Patent: September 14, 2010Assignee: Northern Innovations and Formulations Corp.Inventors: Paul T. Gardiner, Derek E. Woodgate, Mark S. Gilbert, Robert W. Thoburn
-
Publication number: 20100227791Abstract: Disclosed is the use of compounds of formula (I) wherein X, Y and Z are as defined in the description of the invention, for the preparation of an antitumor medicament, optionally in combination with different biologically active substances.Type: ApplicationFiled: January 7, 2010Publication date: September 9, 2010Inventors: Gianfranco Peluso, Menotti Calvani
-
Publication number: 20100226870Abstract: The present invention relates to the use of creatine compounds such as, for example, creatine, creatine phosphate or analogs of creatine, such as creatine-pyruvate, creatine-ascorbate, cyclocreatine, 3 guanidinopropionic acid, guanidinoacetate, homocyclocreatine, guanidino benzoates as energy generating systems and antioxidants for preservation of skin against adverse aging effects and damage secondary to insults such as harmful sun radiations, stress and fatigue. The creatine compounds which can be used in the present method include (1) creatine, creatine phosphate and analogs of these compounds which can act as substrates or substrate analogs for creatine kinase; (2) molecules that mimic the biological activity of creatine (3) molecules that modulate the creatine kinase system.Type: ApplicationFiled: September 17, 2009Publication date: September 9, 2010Applicant: AVICENA GROUP, INC.Inventor: Rima KADDURAH-DAOUK
-
Publication number: 20100227895Abstract: A method for the treatment and preventative care of equine laminitis includes effective administration of the amino acid L-tyrosine, alone, or in conjunction with choline bitartrate, niacin, and/or d-calcium pantothenate to regulate and restore hormonal balance, blood pressure and normal catecholamine synthesis. Tyrosine administration fosters proper vasculation in the equine's body, and specifically promotes proper circulation in and to the hoof and laminae.Type: ApplicationFiled: March 5, 2009Publication date: September 9, 2010Applicant: MPCO- THE MAGIC POWDER COMPANYInventors: Raymond F. LeRoy, Susan E. K. Cook
-
Publication number: 20100221330Abstract: An oral control release formulation for releasing at least one betaine after oral administration to a human, said formulation comprising at least one pharmaceutically acceptable means ensuring an at least partial floating of the formulation releasing at least one betaine in the gastro-intestinal tractus.Type: ApplicationFiled: February 11, 2010Publication date: September 2, 2010Inventor: Jallal Messadek
-
Patent number: 7780990Abstract: The present invention provides pharmaceutical compositions and methods for the treatment of diabetes mellitus using combination therapy. The compositions relate to a compound selected from one or more of betaines, lipidic betaines, betaine lipids and an antidiabetic agent such as sulfonylureas, biguanides, glitazones, .alpha.-glucosidase inhibitors, potassium channel antagonists, aldose reductase inhibitors, glucagon antagonists, activators of RXR, insulin therapy or other anti-obesity agent. The methods include the administration of the combination of compound of Formula I with antidiabetic agent where the two components are delivered in a simultaneous manner, where the compound selected from one or more of betaines, lipidic betaines, betaine lipids is administered first, followed by the antidiabetic agent, as well as wherein the antidiabetic agent is delivered first followed by the compound selected from one or more of betaines, lipidic betaines, betaine lipids.Type: GrantFiled: August 14, 2007Date of Patent: August 24, 2010Inventor: Jallal Messadek
-
Publication number: 20100210608Abstract: The invention describes the use of betaine for treating and preventing arterites. The invention also describes an orally administered composition for treating arterites and, in particular, intermittent claudication, said composition containing, as an active ingredient, an active therapeutic quantity of betaine glycine by single dose. The invention particularly describes a medicament provided for treating a patient suffering from an intermittent claudication caused by peripheral circulatory disorders such as arteriosclerosis obliterans or by thromboangiitis obliterans.Type: ApplicationFiled: March 17, 2010Publication date: August 19, 2010Inventor: Jallal Messadek
-
Publication number: 20100210724Abstract: A method for modifying the properties of a suspension of solid or liquid particles in an aqueous medium, includes the step of adding to the suspension or to the aqueous medium a polymer prepared by inverse emulsion polymerization of monomers Ab, comprising a betaine group, and of nonionic monomers Ba included in an aqueous phase dispersed in the form of droplets in a hydrophobic external phase, wherein the molar ratio of the monomers Ab to the monomers Ba is from about 4/96 to about 40/60, the polymer exhibits an intrinsic viscosity of greater than 600 mL/g, the reduced specific viscosity being measured by dissolving the polymer in a 20% by weight aqueous NaCl solution.Type: ApplicationFiled: February 3, 2010Publication date: August 19, 2010Applicant: RHODIA OPERATIONSInventors: Arnaud Cadix, Chi-Thanh Vuong, Bruno Langlois, Marie-Pierre Labeau
-
Publication number: 20100209541Abstract: Buccal aerosol sprays or capsules using polar and non-polar solvent have now been developed which provide biologically active compounds for rapid absorption through the oral mucosa, resulting in fast onset of effect. The buccal polar compositions of the invention comprise formulation I: aqueous polar solvent, active compound, and optional flavoring agent; formulation II: aqueous polar solvent, active compound, optionally flavoring agent, and propellant; formulation III: non-polar solvent, active compound, and optional flavoring agent; and formulation IV: non-polar solvent, active compound, optional flavoring agent, and propellant.Type: ApplicationFiled: January 22, 2010Publication date: August 19, 2010Inventor: Harry A. DUGGER, III
-
Publication number: 20100210725Abstract: A method for grafting a copolymer onto a polyolefin substrate includes the following steps: (a) irradiating the substrate with ionizing radiation to obtain an activated polyolefin substrate, (b) bringing into contact the activated polyolefin substrate with a mixture of at least two compounds in distilled water including: (i) from 10 to 40% by volume, related to the total volume of the reaction medium, of a hydrophilic unsaturated monomer selected from monomers having the formula: wherein R1 is H or methyl, R2 is —COOH, —NH2, —CON(R3)2, and R3 is H or methyl, (ii) from 20 to 50% by volume, related to the total volume of the reaction medium, of an antimicrobial agent having an average molecular weight of at least 200 g·mol?1, to thereby form a copolymer-grafted polyolefin substrate. Copolymer-grafted polyolefin substrates obtained by this method and a packaging material including copolymer-grafted polyolefin substrate are disclosed.Type: ApplicationFiled: September 11, 2008Publication date: August 19, 2010Applicant: INSTITUT NATIONAL DE LA RECHERCHE AGRONOMIQUE-INRAInventors: Anne-Marie Riquet, Nishat Anjum
-
Publication number: 20100197626Abstract: The present invention provides various biomarkers of depression. The present invention also provides various methods of using the biomarkers, including methods for diagnosis of depression, methods of determining predisposition to depression, methods of monitoring progression/regression of depression, methods of assessing efficacy of compositions for treating depression, methods of screening compositions for activity in modulating biomarkers of depression, methods of treating depression, as well as other methods based on biomarkers of depression.Type: ApplicationFiled: May 8, 2007Publication date: August 5, 2010Inventors: Lisa A. Paige, Matthew W. Mitchell, Anne Evans, Don Harvan
-
Publication number: 20100184664Abstract: The present invention provides a method of improving the visual acuity of a person in need thereof which comprises topically administering to said person, in an effective amount, an ophthalmic composition comprising an aqueous carrier component; and an effective amount of a tonicity component comprising a material selected from a combination of compatible solute agents, wherein said combination of compatible solute agents comprises two polyol components and one amino acid component and wherein said polyol components are erythritol and glycerol and said amino acid component is carnitine.Type: ApplicationFiled: October 6, 2009Publication date: July 22, 2010Inventors: Peter A. Simmons, Joseph Vehige
-
Publication number: 20100172964Abstract: Disclosed is a technique for allowing an active ingredient as an agent for improving or maintaining the dermal environment to reach a dermis. Specifically disclosed is a vesicle comprising the following components 1) to 3): 1) an ?,?-bis(?-N—(C10-30) acylglutamyl) lysine and/or a salt thereof; 2) ceramide and/or a derivative thereof; and 3) one or more selected from a glycerin fatty acid ester, a polyglycerin fatty acid ester and a pyroglutamic acid glycerin fatty acid ester. The acyl group in the ?,?-bis(?-N—(C10-30) acylglutamyl) lysine is preferably a lauroyl group. The ceramide or the derivative thereof is preferably ceramide type-2 or ceramide type-3. The vesicle can encapsulate an active ingredient. The vesicle can be contained in an external preparation for the skin.Type: ApplicationFiled: April 10, 2008Publication date: July 8, 2010Applicant: POLA CHEMICAL INDUSTRIES INC.Inventors: Hidetaka Akatsuka, Hitoshi Imamura, Yasuyuki Ishihara
-
Publication number: 20100137393Abstract: An in vitro method for predicting the onset of type 1 diabetes (T1 D) in a subject, comprises the steps of: (a) measuring the concentration of at least one amino acid, amino acid derivative or amino acid metabolite in a biological sample taken from the subject; (b) determining the subject's HLA genotype; (c) assigning the subject's genetic risk of developing T1 D on the basis of the subject's HLA genotype; (d) combining the information obtained in step (a) with the information in step (c); and (e) predicting the likelihood of onset of T1 D based upon the combination of step (d). The diagnostic method can be used to select target subjects for T1 D prophylactic treatment, and as part of a T1 D preventative treatment regime for neonates having a likelihood of developing childhood T1 D.Type: ApplicationFiled: July 30, 2007Publication date: June 3, 2010Inventors: Gian Franco Bottazzo, Mattia Locatelli
-
Publication number: 20100112075Abstract: Microparticles or granules intended for use in the zootechnical field, constituted by a core which contains a substance having a pharmacological action, a food supplement or a diagnostic medium, intimately mixed or adsorbed with a hydrated silicate of magnesium, aluminum, calcium and sodium (smectite, montmorillonite or bentonite); the core is coated with a double fatty layer constituted by two fats or waxes, of which the one having the highest melting point constitutes the inner layer while the one having the lowest melting point is arranged so as to form the outer layer.Type: ApplicationFiled: July 31, 2007Publication date: May 6, 2010Applicant: EURHEMA S.R.I.Inventors: Ruggero Bettini, Lauro Arduini, Francesca Bertolini, Claudia Camellini
-
Patent number: 7700074Abstract: Chronic alcoholism is a diverse and heterogeneous disorder that can be dichotomized into cognitively intact and cognitively impaired subgroups. At a molecular level, ethanol has been shown to have both acute and chronic effects on: Membrane biophysical properties, Membrane composition and metabolism, Protein phosphorylation, Lipid metabolic signaling, Lipoprotein transport of cholesterol. Actual molecular underpinnings are determined for cognitive impairment seen in some chronic alcoholism subjects including molecular/metabolic alterations of phospholipid and ganglioside metabolisms.Type: GrantFiled: August 23, 2005Date of Patent: April 20, 2010Inventors: Jay W. Pettegrew, Kanagasabai Panchalingam
-
Publication number: 20100093858Abstract: Use of L-carnitine and/or of one or more alkanoyl L-carnitines or one of their pharmaceutically acceptable salts for the preparation of an opthalmic physiological supplement or medicament in the form of eye-drops, for the treatment of corneal diseases.Type: ApplicationFiled: December 18, 2009Publication date: April 15, 2010Applicant: SIGMA-TAU INDUSTRIE FARMACEUTICHE RIUNITE S.P.A.Inventors: Aleardo Koverech, Nicola Pescosolido
-
Publication number: 20100093859Abstract: Compositions and methods useful to enhance neurologic development of a growing animal are disclosed.Type: ApplicationFiled: February 22, 2008Publication date: April 15, 2010Applicant: Hill's Pet Nutrition, Inc.Inventors: Ryan Michael Yamka, Kim Gene Friesen, Steven Curtis Zicker
-
Patent number: RE42645Abstract: Nutritional or therapeutic compositions containing glutamic acid, cystine, glycine and a selenium precursor and methods for their utilization to increase glutathione synthesis and thereby enhance the immune system are described.Type: GrantFiled: March 9, 2006Date of Patent: August 23, 2011Inventor: Albert Crum